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Abstract
Background: Dyspnea while performing the activities of daily living has been suggested to be a better
measurement than peak dyspnea during exercise. Furthermore, the inspiratory capacity (IC) has been shown to be
more closely related to exercise tolerance and dyspnea than the FEV1, because dynamic hyperinflation is the main
cause of shortness of breath in patients with COPD. However, breathlessness during exercise is measured in most
studies to evaluate this relationship.
Purpose: To evaluate the correlation between breathlessness during daily activities and airflow limitation or static
hyperinflation in COPD.
Methods: We examined 167 consecutive outpatients with stable COPD. The Baseline Dyspnea Index (BDI) was
used to evaluate dyspnea with activities of daily living. The relationship between the BDI score and the clinical
measurements of pulmonary function was then investigated.
Results: The Spearman rank correlation coefficients (Rs) between the BDI score and the FEV1(L), FEV1(%pred) and
FEV1/FVC were 0.60, 0.56 and 0.56, respectively. On the other hand, the BDI score also correlated with the IC, IC/
predicted total lung capacity (TLC) and IC/TLC (Rs = 0.45, 0.46 and 0.47, respectively). Although all of the
relationships studied were strongly correlated, the correlation coefficients were better between dyspnea and
airflow limitation than between dyspnea and static hyperinflation. In stepwise multiple regression analyses, the BDI
score was most significantly explained by the FEV1 (R
2 = 26.2%) and the diffusion capacity for carbon monoxide (R
2
= 14.4%) (Cumulative R
2 = 40.6%). Static hyperinflation was not a significant factor for clinical dyspnea on the
stepwise multiple regression analysis.
Conclusion: Both static hyperinflation and airflow limitation contributed greatly to dyspnea in COPD patients.
Keywords: Chronic obstructive pulmonary disease, Airflow limitation, Hyperinflation, Dyspnea, Baseline Dyspnea
Index
Background
Dyspnea is multifactorial, but static lung hyperinflation
and its increase during exercise (dynamic hyperinflation)
is believed to be the most important in subjects with
chronic obstructive pulmonary disease (COPD) [1-3]. It
has been reported that indices related to hyperinflation,
such as the inspiratory capacity (IC), are more closely
related to exercise tolerance and dyspnea than the
forced expiratory volume in 1 second (FEV1) or forced
vital capacity (FVC) [4-8]. The Borg scale is frequently
used during exercise as a marker of laboratory dyspnea
in physiological investigations to evaluate this relation-
ship. Furthermore, Casanova and colleagues proved that
static lung hyperinflation estimated by the inspiratory
capacity-to-total lung capacity (IC/TLC) ratio is a pre-
dictor of all-cause and respiratory mortality in patients
with COPD, independent of the FEV1 [9].
The outcome measurements for dyspnea can be
broadly divided into those that assess breathlessness
during exercise (laboratory dyspnea), and those that
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cal dyspnea). Using factor analysis, Hajiro et al. [10]
reported that various clinical dyspnea ratings were vir-
tually identical for evaluating dyspnea in COPD patients.
On the other hand, dyspnea at the end of maximal exer-
cise may provide a different type of information regard-
ing dyspnea [10]. It has also been reported that dyspnea
during daily activities was mores i g n i f i c a n t l yc o r r e l a t e d
with objective and subjective measurements of COPD
than dyspnea at the end of exercise, and that the former
was more predictive of mortality [11]. Therefore, dys-
pnea while performing the activities of daily living is
considered to be a better measurement for evaluating
the disease severity of COPD than peak dyspnea during
exercise.
We hypothesized that static hyperinflation may be
more closely related to clinical dyspnea than laboratory
dyspnea, since there is a close relationship between the
IC and exercise performance and dyspnea in COPD.
The purpose of this observational study was to evaluate
the correlation between breathlessness during daily
activities measured using the Baseline Dyspnea Index
(BDI) and airflow limitation or static hyperinflation in
COPD.
Methods
A total of 167 consecutive patients with stable COPD
defined as a FEV1/FVC of less than 0.7 for all measure-
ments made during the previous 6 months were
recruited at the outpatient clinic of the Respiratory divi-
sion of Kyoto-Katsura Hospital. The entry criteria
included: (1) a diagnosis of COPD and an age over 40
years; (2) a self-reported current or former smoker; (3)
regular attendance at our clinic for more than 6 months
to avoid substantial changes in subjective parameters
brought about by new medical interventions; and (4) no
changes in the treatment regimen for more than 4
weeks. Patients with any history suggestive of asthma, a
never-smoker, an exacerbation of their COPD over the
preceding 6 weeks, previous inflammatory changes
revealed on chest radiographs that could influence pul-
monary function (for example, a previous thoracoplasty
or tuberculous sequelae), or any other illnesses, were
excluded. All eligible patients underwent the following
examinations on the same day. None of the results from
the 167 patients in the present study have been pub-
lished elsewhere. Informed consent was obtained from
all participants.
On the evaluation day, the patients completed their
pulmonary function tests, arterial blood gas (ABG) ana-
lyses, blood investigation, chest X-rays and dyspnea
measurements. The patients were requested to stop
using tiotropium bromide for 24 hours before, and were
also asked to discontinue the use of other inhaled
bronchodilators for at least 12 hours before the assess-
ment. According to the method described by the ATS/
ERS Task Force in 2005 [12], three acceptable spiro-
metric flow-volume curves were recorded with the
patient sitting using a calibrated 2.0-L syringe before
every measurement. The largest FEV1 and the largest
FVC among three maneuvers were then analyzed. The
predicted values for the FEV1 and vital capacity (VC)
were calculated according to the proposal from the
Japan Society of Chest Diseases [13]. The residual
volume (RV) was measured by the closed-circuit helium
method, and the diffusion capacity for carbon monoxide
(DLco) was measured using the single-breath technique
(CHESTAC-65 V; Chest, Tokyo, Japan). Chest radio-
graphs were obtained in all patients. ABG analyses were
also performed. In cases associated with long-term dom-
iciliary oxygen therapy, the arterial blood was obtained
while breathing the predetermined oxygen therapy.
Blood was collected to measure the levels of plasma
brain natriuretic peptide (BNP) by a chemiluminescent
enzyme immunoassay [14].
To assess dyspnea, the Japanese version of the Base-
line Dyspnea Index (BDI) was used [10,15,16], which
has been previously validated. The BDI recognizes five
grades for each of the following categories: functional
impairment, magnitude of task and magnitude of effort,
with higher scores indicating more severe dyspnea. The
original Japanese version of the BDI/TDI was completed
and the first two studies for validation were published in
1998 [10,16]. The newer Japanese version of the BDI/
TDI was subsequently developed and replaced the older
version in 2008. However, the former Japanese version
of the BDI was used in the present study.
Statistical Analysis
All results are expressed as means ± SD. The relation-
ship between two sets of data was analysed by both
Spearman’s rank correlation and by Pearson’sc o r r e l a -
tion tests. Multiple regression analysis was performed to
determine the association of the various variables with
the BDI scores. The independent variables analysed
were: age (years), smoking (pack-years), body mass
index (BMI) (kg/m
2), FEV1 (L), IC/predicted TLC, DLCO
(mL/min/mmHg), PaO2 (mmHg) and blood BNP levels
(pg/mL). The FEV1 and IC/predicted TLC were selected
as indices for airflow limitation and static hyperinflation,
respectively. Multiple linear regressions were obtained
by the standard, forward and backward stepwise meth-
o d s .Apv a l u eo fl e s st h a n0 . 0 5w a sc o n s i d e r e dt ob e
statistically significant.
Results
A total of 167 consecutive patients (147 males) were
studied at the outpatient clinic between September 2007
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Page 2 of 7and September 2008. Their demographic details as well
as pulmonary function test data are shown in Table 1.
The average age and FEV1 were 71.6 ± 8.7 years and
1.52 ± 0.72 L, since the patient group included cases
with mild to severe airflow limitation. All patients
except for two were treated with inhaled bronchodila-
tors plus high doses of inhaled corticosteroids. Six sub-
jects were also given oral corticosteroids. Eight patients
were treated with long-term oxygen therapy. Three sub-
jects were managed with non-invasive positive pressure
ventilation at home. The frequency distribution histo-
grams of the BDI scores in the present study are shown
in Figure 1. The scores are skewed towards the very
mild end of the scale.
Table 1 shows the correlations between the BDI and
22 characteristics, and statistically significant correla-
tions were observed between the BDI scores and 20
characteristics excluding the PaCO2. There was no cor-
relation between the acid-base balance and the BDI
scores. Table 2 shows simple correlations between
three airflow limitation characteristics and the BDI
scores, as well as between three static hyperinflation
characteristics and the BDI scores. The Spearman rank
correlation coefficients between the BDI score and the
FEV1 (L), FEV1 (%pred) and FEV1/FVC were 0.60, 0.56
and 0.56, respectively. On the other hand, the BDI
score was also correlated with the IC, IC/predicted
Table 1 Demographic details and correlations with the BDI score (Spearman’s rank correlation test) in 167 subjects
with stable COPD
variable units mean SD max min Correlations with BDI score
Rs p value
Age years 71.6 8.7 90 40 -0.25 0.0014
BMI kg/m
2 21.1 3.2 32.2 13.3 0.17 0.0320
Cumulative Smoking pack-years 71 42 268 4 -0.23 0.0033
VC Liters 3.21 0.91 5.31 0.97 0.45 < 0.0001
VC % pred 102.6 22.8 156.2 38.6 0.48 < 0.0001
FVC Liters 3.05 0.89 5.25 0.99 0.47 < 0.0001
FVC % pred 97.4 22.5 147.9 40.9 0.51 < 0.0001
FEV1 Liters 1.52 0.72 3.46 0.39 0.60 < 0.0001
FEV1 % pred 68.5 27.4 133.0 13.0 0.60 < 0.0001
FEV1/FVC % 48.2 13.9 69.9 22.1 0.56 < 0.0001
TLC Liters 5.65 1.15 8.49 2.86 0.24 0.0022
TLC % pred 111.3 17.5 160.6 57.3 0.24 0.0022
IC Liters 2.09 0.68 3.57 0.69 0.45 < 0.0001
IC/TLC % 36.8 8.6 60.3 11.8 0.47 < 0.0001
IC/predicted TLC % 41.1 11.7 66.5 12.2 0.46 < 0.0001
DLco mL/min/mmHg 10.26 5.45 24.66 0.22 0.55 < 0.0001
DLco % pred 65.0 27.3 133.7 2.5 0.53 < 0.0001
DLco/VA mL/min/mmHg/L 2.35 1.16 6.52 0.03 0.52 < 0.0001
PaO2 mmHg 80.1 11.5 104.8 50.3 0.48 < 0.0001
PaCO2 mmHg 40.5 4.8 63.3 30.7 0.00 0.98
pH (arterial blood) 7.43 0.03 7.53 7.33 0.04 0.64
BNP pg/mL 46.5 78.8 521.0 3.0 -0.23 0.0033
BDI score (0-12) 8.5 2.8 12 0 - -
Gender 147 Male/20 Female
Smoking Status 29 Current/138 Former

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Figure 1 Frequency distribution histograms of the BDI scores.
Lower scores indicate more severe dyspnea.
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tively). Although all of the relationships studied were
strongly correlated, the correlation coefficients were
better between dyspnea and airflow limitation than
between dyspnea and static hyperinflation. These
results were similar when the Pearson’s correlation
coefficient was used instead (Table 2).
Stepwise multiple regression analyses were per-
formed to identify those variables that could best pre-
dict the dyspnea assessed by the BDI score. The FEV1
(L) and IC/predicted TLC, the airflow limitation and
static hyperinflation characteristics with the strongest
simple correlations with dyspnea in Table 2, as well as
six other independent variables from Table 1 were
included. We found out that the airflow limitation
(FEV1) and diffusion capacity for carbon monoxide
(DLco) significantly accounted for 26.2% and 14.4% of
the variance, respectively (Table 3). Since the cumula-
tive R
2 was 0.406, unknown factors still contribute to
the BDI score. However, static hyperinflation was not a
significant factor for clinical dyspnea using stepwise
multiple regression analysis. The results were the same
when we analyzed the 101 subjects with moderate to
very severe COPD (excluding mild COPD) (data not
shown).
Discussion
The reason why patients with COPD feel subjective dys-
pnea is a simple question. However, answering this
question is not simple, and clinicians need to under-
stand the mechanisms responsible for dyspnea. It is
widely accepted that the major limitation to exercise
performance and the perception of breathlessness in
COPD can be attributed to dynamic hyperinflation,
although activity limitation and dyspnea in COPD is
multifactorial. This has been explained by the following
mechanism [1-3]. In COPD, the end-expiratory lung
volume (EELV) is elevated as compared to healthy con-
trols. During spontaneous breathing at rest in patients
with expiratory flow limitations, the EELV is maintained
at a level above the statically determined relaxation
volume of the respiratory system. In flow-limited
patients, the mechanical time-constant for lung empty-
ing is increased in many alveolar units, but the expira-
tory time available during quiet breathing is often
insufficient to allow the EELV to completely decline to
its normal relaxation volume, and thus air trapping
results. Dynamic hyperinflation occurs in flow-limited
patients under the condition of increased ventilatory
demand during exercise. Since the total lung capacity
does not change during activity, the decrease in the IC
must reflect an increase in the dynamic EELV, or the
extent of dynamic hyperinflation. With the limitation of
the tidal volume increase during exercise, dynamic
hyperinflation results in restrictive mechanical con-
straints which, in the extreme, can lead to alveolar
hypoventilation during exercise. In patients with COPD,
breathing to higher lung volumes increases the total
respiratory work, and thus potentiates the perception of
breathlessness, which favors a decrease in physical
activity.
T h er a t ea n dm a g n i t u d eo fd y n a m i ch y p e r i n f l a t i o n
during exercise is generally measured in the laboratory
setting by serial inspiratory capacity measurements.
O’Donnell et al. reported that the exercise endurance
time, Borg dyspnea ratings at the isotime near end-exer-
cise, and IC are very reproducible indices [5], and that
Table 2 Correlations of the BDI score with airflow limitation and static hyperinflation
Spearman’s rank correlation coefficients Pearson’s correlation coefficient
Rs p value R p value
Dyspnea vs. Airflow limitation
BDI score vs. FEV1 (L) 0.60 < 0.0001 0.60 < 0.0001
BDI score vs. FEV1 (%pred) 0.56 < 0.0001 0.57 < 0.0001
BDI score vs. FEV1/FVC 0.56 < 0.0001 0.57 < 0.0001
Dyspnea vs. Static Hyperinflation
BDI score vs. IC (L) 0.45 < 0.0001 0.48 < 0.0001
BDI score vs. IC/predicted TLC 0.46 < 0.0001 0.51 < 0.0001
BDI score vs. IC/TLC 0.47 < 0.0001 0.48 < 0.0001
Table 3 Results of stepwise multiple regression analyses
to identify those variables that best predicted dyspnea
assessed by the BDI score
BDI score
Independent variables
Age (years) -
Smoking (pack-years) -
BMI (kg/m
2)-
FEV1 (L) 0.262
IC/predicted TLC -
DLCO (mL/min/mmHg) 0.144
PaO2 (mmHg) -
BNP (pg/mL) -
Cumulative R
2 0.406
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improve the exercise endurance time by 32% on average.
This improvement correlated best with the IC improve-
ment, but not with the FVC or FEV1 improvements, and
the change in the Borg dyspnea ratings at the isotime
near end-exercise also correlated well with the IC
improvement [6]. An increased IC means reduced rest-
ing lung hyperinflation. Using a similar mechanism, the
use of tiotropium bromide, salmeterol, or a fluticasone
propionate/salmeterol combination was associated with
sustained reductions in lung hyperinflation at rest and
during exercise. The resultant increases in inspiratory
capacity permitted a greater expansion of the tidal
volume, and contributed to improvements in both exer-
cise endurance and exertional dyspnea [4,7,8].
In the present study, airflow limitation may have been
a more important cause of clinical dyspnea than static
hyperinflation. This clearly contradicts the above men-
tioned hypothesis, and the results of the laboratory exer-
cise tests that are based upon it. Why is our result
different? The first issue to consider is the different dys-
pnea evaluation methods used. We wanted to assess
overall breathlessness during daily activities (clinical dys-
pnea) using the BDI score in the present study, whereas
the Borg dyspnea ratings at isotime exercise has been
used in most laboratory studies. Dyspnea during exer-
cise using the Borg scale may provide a different type of
information regarding dyspnea than clinical dyspnea
[11]. Therefore, if the cause of COPD dyspnea is
hypothesized to be dynamic hyperinflation, then it is
necessary to evaluate clinical dyspnea instead of labora-
tory dyspnea.
Murariu et al. used a method similar to ours, and
evaluated their maximal symptom-limited exercise on a
cycle ergometer. Their correlation coefficients between
the Wmax with the IC and FEV1 were 0.81 and 0.54,
respectively, and a multiple regression model using the
Wmax as the dependent variable revealed that the IC
was the only significant contributor to the Wmax. They
also reported that the FEV1 was not statistically signifi-
cant [17]. Their study used the Wmax as the outcome,
whereas we used clinical dyspnea instead. Although the
methods of their analysis were similar, their comparison
between airflow limitation and static hyperinflation
resulted in completely different conclusions. Therefore,
using clinical dyspnea as the outcome in our study
probably explains the different results.
The main reason why dynamic hyperinflation can be
hypothesized to be the main cause of dyspnea is the
strong correlation between dynamic hyperinflation and
dyspnea. Some researchers have argued against this
hypothesis, since the presence of dynamic hyperinflation
is not a universal finding during exercise [18]. We did
not directly evaluate dynamic hyperinflation, but instead
used the IC, which is the index for static hyperinflation.
The IC may reflect dynamic hyperinflation inaccurately.
Nevertheless, in the study conducted by O’Donnell et
al., the correlation between the magnitude of the
changes in the IC and Borg scores was strong, and they
concluded that this explained why dynamic hyperinfla-
tion was causing dyspnea. However, correlations in
cross-sectional studies and longitudinal studies do not
necessarily match, and a statistical approach such as
correlation coefficients may not resolve this issue. Air-
flow limitation causes dynamic hyperinflation, and
hence airflow limitation, dynamic hyperinflation and
dyspnea may be considered as the top of a pyramid, and
it may not be necessary to consider them in a linear,
causal relationship.
In the present study, airflow limitation explained only
26% of the BDI score, and airflow limitation plus the dif-
fusing capacity explained an accumulative 41% of the
BDI score. In the literature, it is thought that dyspnea
measures are moderately correlated with pulmonary
function, psychological function, and walking tests [19].
For example, a simple correlation between the BDI score
and FEV1 has been reported to be statistically significant,
with a correlation coefficient of 0.22-0.58 [10,19-21].
Although as per pulmonary function, the FEV1 and FVC
are often evaluated for a correlation with clinical dys-
pnea, the correlations between the FEV1, static hyperin-
flation and clinical dyspnea have not been evaluated
simultaneously. In addition, to our knowledge, this is the
first study which proved that the diffusing capacity was a
significant contributor to clinical dyspnea. This may indi-
cate that emphysema-predominant subjects with COPD
are conscious of stronger dyspnea. Our results obtained
from the stepwise multiple regression analyses also indi-
cate that there are other unmeasured factors that explain
clinical dyspnea. Wijkstra et al. [22] reported that the
transfer factor for carbon monoxide (TLCO)w a ss t r o n g l y
correlated with the six minute walking test and with the
maximal work load, and that backward linear regression
analysis selected the TLCO and peak esophageal pressure
during a maximal semistatic maneuver as the most signif-
icant determinants for exercise performance. However,
although they discussed the mechanism of correlation
between the TLCO and exercise capacity, their cause-
effect relationship is still unknown. Similarly, the
mechanism of correlation between the diffusing capacity
and clinical dyspnea is also unknown
There are also important considerations in the clinical
practice setting. A common misunderstanding is that
hypoxemia is causing dyspnea, and proper oxygen
administration alone is enough. We want to emphasize
that oxygen administration to alleviate dyspnea in
COPD patients whose PaO2 is over 60 mmHg is the
wrong treatment.
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systemic disease, we should consider that other many
factors possibly related to dyspnea. Since depression and
anxiety are frequent in subjects with COPD, they have
been investigated for their role in clinical dyspnea [19].
Unfortunately, a psychological assessment was not
included in the present study.
We measured the BNP levels to investigate whether
heart failure can play a role in dyspnea in COPD
patients. It has been reported that BNP can be used to
differentiate heart failure from respiratory diseases,
including COPD, in patients with dyspnea [23]. Further-
more, COPD patients were reported to have higher
levels of BNP as compared to controls [24]. Although
the Spearman rank correlation test revealed a significant
correlation between BNP levels and dyspnea, the step-
wise multiple regression analysis did not. This does not
explain what elevated BNP levels in subjects with COPD
mean clinically, but the magnitude of this elevation may
depend on the disease severity instead of dyspnea.
Some limitations of the present study should be
mentioned. Most of the issues are related to the study
design. First, this study is based just on correlation
analysis, which is not the best way to detect the cause
of a phenomenon. Second, although stepwise multiple
regression analyses were performed to compare the
relative contributions between airflow limitation and
static hyperinflation on clinical dyspnea, over half of
the contributory factors are still unknown. Third, we
analyzed the FEV1 (L), FEV1 (%pred) and FEV1/FVC as
for airflow limitation. Although the FEV1 is very popu-
lar, it may be an older index of flow limitation. Other
methods, including the tidal volume over the envelope
in the flow-volume loop or the negative expiratory
pressure during tidal breathing, should be compared
against any measurements of clinical or laboratory dys-
pnea. The present study was also limited by the small
number of participants and distinct male preponder-
ance of the subjects. Although the latter is typically
observed in subjects with COPD in Japan, generaliza-
tion of these results to women with COPD may be
uncertain.
Conclusion
Both static hyperinflation and airflow limitation contrib-
uted greatly to dyspnea in COPD patients. Our conclu-
sion does not support the hypothesis that the
perception of breathlessness in COPD is attributable to
static hyperinflation. One possible reason for this incon-
sistent conclusion may be that different types of dyspnea
(clinical dyspnea vs. laboratory dyspnea) have been
assessed in previous investigations.
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